Twist Bioscience (TWST) Competitors $36.75 -0.04 (-0.11%) Closing price 07/1/2025 04:00 PM EasternExtended Trading$36.66 -0.09 (-0.23%) As of 09:18 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock TWST vs. BPMC, BBIO, VRNA, ROIV, RVMD, ELAN, LEGN, TGTX, GRFS, and LNTHShould you be buying Twist Bioscience stock or one of its competitors? The main competitors of Twist Bioscience include Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Elanco Animal Health (ELAN), Legend Biotech (LEGN), TG Therapeutics (TGTX), Grifols (GRFS), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry. Twist Bioscience vs. Its Competitors Blueprint Medicines BridgeBio Pharma Verona Pharma PLC American Depositary Share Roivant Sciences Revolution Medicines Elanco Animal Health Legend Biotech TG Therapeutics Grifols Lantheus Blueprint Medicines (NASDAQ:BPMC) and Twist Bioscience (NASDAQ:TWST) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability. Which has more volatility and risk, BPMC or TWST? Blueprint Medicines has a beta of 0.89, indicating that its share price is 11% less volatile than the S&P 500. Comparatively, Twist Bioscience has a beta of 2.41, indicating that its share price is 141% more volatile than the S&P 500. Which has preferable earnings and valuation, BPMC or TWST? Blueprint Medicines has higher revenue and earnings than Twist Bioscience. Blueprint Medicines is trading at a lower price-to-earnings ratio than Twist Bioscience, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBlueprint Medicines$508.82M16.29-$67.09M-$2.47-51.96Twist Bioscience$312.97M7.04-$208.73M-$3.25-11.31 Is BPMC or TWST more profitable? Blueprint Medicines has a net margin of -27.70% compared to Twist Bioscience's net margin of -54.98%. Twist Bioscience's return on equity of -33.48% beat Blueprint Medicines' return on equity.Company Net Margins Return on Equity Return on Assets Blueprint Medicines-27.70% -64.60% -17.22% Twist Bioscience -54.98%-33.48%-25.34% Does the media refer more to BPMC or TWST? In the previous week, Blueprint Medicines had 5 more articles in the media than Twist Bioscience. MarketBeat recorded 9 mentions for Blueprint Medicines and 4 mentions for Twist Bioscience. Blueprint Medicines' average media sentiment score of 1.23 beat Twist Bioscience's score of 0.68 indicating that Blueprint Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Blueprint Medicines 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Twist Bioscience 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend BPMC or TWST? Blueprint Medicines currently has a consensus price target of $128.06, suggesting a potential downside of 0.22%. Twist Bioscience has a consensus price target of $50.40, suggesting a potential upside of 37.14%. Given Twist Bioscience's stronger consensus rating and higher possible upside, analysts plainly believe Twist Bioscience is more favorable than Blueprint Medicines.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Blueprint Medicines 0 Sell rating(s) 17 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.27Twist Bioscience 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70 SummaryBlueprint Medicines beats Twist Bioscience on 9 of the 15 factors compared between the two stocks. Get Twist Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for TWST and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TWST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TWST vs. The Competition Export to ExcelMetricTwist BioscienceMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.20B$2.85B$5.48B$8.94BDividend YieldN/A2.69%5.38%4.12%P/E Ratio-11.3121.1726.2219.74Price / Sales7.04262.85394.92109.12Price / CashN/A41.8936.4957.06Price / Book4.557.237.915.37Net Income-$208.73M-$55.05M$3.15B$248.34M7 Day Performance-0.65%-0.60%0.75%1.67%1 Month Performance18.28%3.77%3.46%4.56%1 Year Performance-22.34%2.20%34.60%18.42% Twist Bioscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TWSTTwist Bioscience4.3388 of 5 stars$36.75-0.1%$50.40+37.1%-24.9%$2.20B$312.97M-11.31990News CoverageBPMCBlueprint Medicines1.736 of 5 stars$128.40+0.2%$128.06-0.3%+17.5%$8.29B$508.82M-51.98640Positive NewsHigh Trading VolumeBBIOBridgeBio Pharma4.7066 of 5 stars$42.17+1.1%$56.67+34.4%+69.8%$8.01B$127.42M-11.95400Analyst ForecastInsider TradeVRNAVerona Pharma PLC American Depositary Share2.57 of 5 stars$97.05+2.9%$101.10+4.2%+483.4%$7.87B$118.54M-48.5330Positive NewsAnalyst ForecastGap UpROIVRoivant Sciences2.0945 of 5 stars$11.50+0.4%$17.50+52.2%+1.0%$7.82B$29.05M-46.00860RVMDRevolution Medicines4.4826 of 5 stars$40.04+1.0%$67.08+67.5%-4.9%$7.46B$11.58M-10.01250Analyst RevisionELANElanco Animal Health2.3312 of 5 stars$13.36-0.7%$15.17+13.5%+2.5%$6.64B$4.43B18.059,000LEGNLegend Biotech2.4049 of 5 stars$33.85-0.4%$76.20+125.1%-21.1%$6.22B$627.24M-57.372,609Positive NewsTGTXTG Therapeutics3.7601 of 5 stars$36.56+1.5%$40.80+11.6%+95.0%$5.80B$329M152.33290GRFSGrifols4.1202 of 5 stars$8.37-4.6%$10.30+23.1%+43.3%$5.75B$7.81B7.1523,822Analyst DowngradeLNTHLantheus4.3359 of 5 stars$80.81+2.0%$130.50+61.5%-0.7%$5.59B$1.53B22.96700 Related Companies and Tools Related Companies Blueprint Medicines Alternatives BridgeBio Pharma Alternatives Verona Pharma PLC American Depositary Share Alternatives Roivant Sciences Alternatives Revolution Medicines Alternatives Elanco Animal Health Alternatives Legend Biotech Alternatives TG Therapeutics Alternatives Grifols Alternatives Lantheus Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TWST) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored379 passengers walked away from thisElon Musk just wrote a $51 million check to back this material’s next phase… Because it’s not just saving l...True Market Insiders | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredThe #1 AI Energy StockNearly $600 billion is projected to be spent on AI data centers this year. That's because the ones being bu...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Twist Bioscience Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Twist Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
